Olveca Duo Tablets 5/20 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Youngil Pharmaceutical Co., Ltd.
MFDS item code 202002910 · Approved 2020.04.23
This product's status changed to Expired on 2025.04.23. It may no longer be sold, so consult a doctor or pharmacist before taking it.
Treatment of essential hypertension not controlled with monotherapy
This medication is used to effectively lower blood pressure in patients with essential hypertension whose blood pressure is not sufficiently controlled with monotherapy of amlodipine or olmesartan medoxomil. This helps to reduce the risk of complications from hypertension and improve cardiovascular health. Therefore, it plays a crucial role in the management of essential hypertension, enhancing the overall health of patients.
This medicine is administered as 1 tablet once daily with water, regardless of meals. If possible, it is recommended that it be taken at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended that the dose be adjusted using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not adequately controlled with monotherapy using either individual component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 mg. The maximum blood pressure-lowering effect occurs within 2 weeks after administration; therefore, adjust the dose at intervals of at least 2 weeks, taking the patient's blood pressure response into account. The recommended doses are as follows. - 5/20 mg: For patients whose blood pressure is not adequately controlled with amlodipine 5 mg or olmesartan medoxomil 20 mg as monotherapy. - 10/20 mg: For patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 mg as monotherapy. - 5/40 mg: For patients whose blood pressure is not adequately controlled with 5/20 mg. - 10/40 mg: For patients whose blood pressure is not adequately controlled with 5/40 mg. ∘Patients with renal impairment: This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil for patients with mild to moderate renal impairment (creatine clearance 20-60mL/min) is 20 mg once daily. Use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients undergoing dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal impairment. ∘Patients with reduced effective intravascular volume: In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients receiving diuretics, particularly those with renal impairment), it is recommended to start treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment: Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 mg once daily, and the maximum dose is 20 mg once daily. Patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics should have their blood pressure and renal function closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See Precautions for Use, section 2. Patients Who Should Not Receive This Medicine.) ∘Elderly patients: In general, start treatment at a low dose. When adjusting the dose, consider the patient's renal or cardiac function and comorbid conditions. In elderly patients, blood pressure should be monitored closely and more frequently.
The safety and efficacy of this medicine have not been established in pediatric patients under 18 years of age.
This drug can cause serious harm or death to the fetus and newborn if administered to pregnant women during the second and third trimesters, so it should be discontinued immediately upon confirmation of pregnancy. This drug should not be used by individuals who are allergic to the active ingredients or similar substances, pregnant or breastfeeding women, patients with severe liver dysfunction, patients with severe aortic stenosis, patients with biliary obstruction, patients on dialysis, patients in shock, certain diabetic patients, and those with severe kidney impairment. Patients with hypotension due to low fluid or sodium levels may exhibit signs of hypotension, so their condition should be closely monitored before administration. Because of the vasodilatory effect, acute hypotension may occur, so caution is needed. It should also be used cautiously in patients with severe heart disease or reduced kidney function and liver dysfunction, as this drug may affect kidney function and regular kidney function tests are recommended. During treatment, side effects such as dizziness, headache, hypotension, orthostatic hypotension, nausea, vomiting, dyspepsia, rash, and edema may occur, and if any abnormal symptoms appear, consultation with healthcare personnel should be sought immediately. This drug may interact with other medications, especially potassium-sparing diuretics, potassium supplements, lithium, and non-steroidal anti-inflammatory drugs, so caution is advised. It is also recommended to avoid grapefruit juice. This drug should not be taken during pregnancy and if planning or currently pregnant, consultation with a doctor is essential. Breastfeeding can allow this drug to pass into breast milk, potentially causing abnormal reactions in the infant, so either breastfeeding should be discontinued or the use of this drug should be stopped. Safety and efficacy in children under 18 have not been established, thus it is not recommended. In elderly patients, drug metabolism may slow down due to reduced kidney and liver function, so start with a low dose and take with caution. In cases of overdose, severe hypotension and symptoms due to vasodilation may occur, requiring immediate medical attention for appropriate treatment. This drug should be kept away from direct sunlight and moisture and stored out of reach of children, and it is advisable not to transfer it to another container.
Not everyone experiences these, and they can vary from person to person.
This medication may be sensitive to air or moisture, so it must be stored in a sealed container. It should also be kept at room temperature, ideally between 1 to 30 degrees Celsius.
White round film-coated tablets
30 tablets/PTP [(10 tablets/PTP x 3)]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Youngil Pharmaceutical Co., Ltd.
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corp.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
JW Pharmaceutical Corporation
CombinationAmlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Korea Hyuntex Pharmaceutical Co., Ltd.
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilseong IS Co., Ltd.
Amlodipine Besylate 13.888mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Ilsung IS Co., Ltd.
CombinationAmlodipine Besylate 6.94mg · Olmesartan Medoxomil 20mg
Tablet · Prescription medication · Combination
Korea United Pharmaceutical Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.